Market capitalization | €1.60b |
Enterprise Value | €1.72b |
PER (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 2.21 |
P/S ratio (TTM) P/S ratio | 2.06 |
P/B ratio (TTM) P/B ratio | 1.44 |
Turnover (TTM) Turnover | €776.60m |
EBIT (operating result TTM) EBIT | €-82.68m |
Cash position | €509.94m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
11 Analysts have issued a Evotec forecast:
11 Analysts have issued a Evotec forecast:
Mar '24 |
+/-
%
|
||
Turnover | 209 209 |
-
|
|
Gross income | 35 35 |
-
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | -27 -27 |
-
|
Net profit | -21 -21 |
-
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Head office | Germany |
CEO | Mario Polywka |
Employees | 5,000 |
Founded | 1993 |
Website | evotec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.